



HAL
open science

A cluster of patients with a recombinant B/F HIV-1 infection: epidemiological, clinical and virological aspects.

Roberto Rossotti, Barbara Foglieni, Chiara Molteni, Manuela Gatti, Irene Guarnori, Ennio La Russa, Daniele Prati, Anna Orani

► To cite this version:

Roberto Rossotti, Barbara Foglieni, Chiara Molteni, Manuela Gatti, Irene Guarnori, et al.. A cluster of patients with a recombinant B/F HIV-1 infection: epidemiological, clinical and virological aspects.. Journal of Medical Virology, 2011, 83 (9), pp.1493. 10.1002/jmv.22142 . hal-00657571

HAL Id: hal-00657571

<https://hal.science/hal-00657571>

Submitted on 7 Jan 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



A cluster of patients with a recombinant B/F HIV-1 infection: epidemiological, clinical and virological aspects.

Journal:	<i>Journal of Medical Virology</i>
Manuscript ID:	JMV-10-2162.R2
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	28-Apr-2011
Complete List of Authors:	Rossotti, Roberto; Alessandro Manzoni Hospital, Infectious Diseases and Tropical Medicine Foglieni, Barbara; Alessandro Manzoni Hospital, Transfusion Medicine and Hematology Molteni, Chiara; Alessandro Manzoni Hospital, Infectious Diseases and Tropical Medicine Gatti, Manuela; Alessandro Manzoni Hospital, Infectious Diseases and Tropical Medicine Guarnori, Irene; Alessandro Manzoni Hospital, Transfusion Medicine and Hematology La Russa, Ennio; Alessandro Manzoni Hospital, Infectious Diseases and Tropical Medicine Prati, Daniele; Alessandro Manzoni Hospital, Transfusion Medicine and Hematology Orani, Anna; Alessandro Manzoni Hospital, Infectious Diseases and Tropical Medicine
Keywords:	HIV-1, non-B subtype, BF recombinant form, response to HAART

SCHOLARONE™
Manuscripts

Table 1. Epidemiological aspects of patients infected with the B/F recombinant clade.

Subject	Age	Sex	Origin	CD4 at diagnosis	Transmission route	Year of diagnosis	CD4 at HAART initiation	CDC state at diagnosis
1	50	M	Eastern shore Lecco lake	823	Heterosexual	2007	214	B2
2	40	M	Lecco	402	Heterosexual	2006	182	A2
3	28	M	Brianza	669	Heterosexual	2008	146	A1
4	30	F	Brianza	1059	Heterosexual	2008	266	A1
5	49	M	Milan	254	Heterosexual	2002	292	B2
6	54	M	High Como lake	418	Heterosexual	2008	420	A2
7	55	F	High Como lake	367	Heterosexual	2008	302	B2
8	45	M	High Como lake	451	Heterosexual	2007	308	A2
9	31	F	Brazil	565	Heterosexual	2007	305	A1
10	46	M	Ivory Coast	509	Heterosexual	2008	//	A1
11	19	F	Kenya	536	Heterosexual	2007	//	A1
12	47	M	Bergamo	432	Bisexual	2007	//	B2
13	52	M	Western shore Lecco lake	712	Homosexual	2009	//	B1


The Table shows epidemiological features of 13 subjects infected with a B/F recombinant strain. Aside from 3 individuals with African and South American origins (patient 9, 10 and 11), the others are Italian who live in the area of catchment of our general hospital. Even though their villages are not far from Lecco, the peculiar physical geography of the area, characterized by small alpine valleys and lakes, leads to a partial isolation of each mountain community, thus social contacts among them are generally uncommon. At diagnosis, they all have a good immunological condition (except patient 5) and there were no C stage conditions; heterosexual transmission was the main route of infection. All patients were diagnosed after 2006, except patient 5, who had an older infection, but he lived in Milan and moved to Lecco only later. CD4+ lymphocyte T cell count at HAART initiation was above 200 cell/mm³, with the exception of patient 2 (who refused to start treatment given the immuno-virological discordance) and patient 3 (who discovered to have a Non-Hodgkin lymphoma soon after the HIV diagnosis).

Table 2. Highly-Active Antiretroviral Therapy, mutational pattern and immuno-virological status at treatment beginning.

Subject	<i>rt</i> mutations	<i>pol</i> mutations	HAART regimen	CD4 cell count	HIV-RNA (log ₁₀)
1	399D	13V, 36I, 72T, 89M	FTC/TDF+EFV	214	3.47
2			FTC/TDF+EFV	182	4.61
3			FTC/TDF+EFV	146	//
4			FTC/TDF+ATV/rtv	266	6.51
5	44A	36I	3TC/ABC+ATV/rtv	292	5.48
6		13V, 36I, 77I	FTC/TDF+EFV	420	5.14
7			3TC/ABC+NVP	302	3.94
8		10I, 13V, 36I	FTC/TDF+ATV/rtv	308	4.18
9		16E, 36I	FTC/TDF+NVP	305	4.89
9	103N, 181C	16E, 36I	FTC/TDF+ATV/rtv	401	3.82

FTC/TDF: emtricitabine/tenofovir; EFV: efavirenz; ATV/rtv: atazanavri/ritonavir; 3TC/ABC: lamivudine/abacavir; NVP: nevirapine. Baseline genotype resistance test did not show any clinically relevant substitution; on the contrary, the second test performed by patient 9 after virological failure showed two typical NNRTI-related mutations (103N and 181C). CD4+ lymphocyte T cell count at HAART initiation was above 200 cell/mm³, with the exception of patient 2 (who refused to start treatment given the immuno-virological discordance) and patient 3 (who discovered to have a Non-Hodgkin lymphoma soon after the HIV diagnosis). A NNRTI-based regimen was started in 6 subjects (with either EFV and NVP), while a PI-based regimen was started in 4 (only with ATV/rtv).


Figure 1. Genome structure of the 13 BF strains identified in this study and the reference CRF12_BF sequence.



Black: subtype B; grey: subtype F. All 13 B/F strains showed the same genomic structure. The sequences for the gag-protease and env regions were used for phylogenetic analysis and genotyping of the subjects. The subtyping function of NCBI showed that the gag-protease sequence was subtype F with a section of subtype B. This was confirmed by SimPlot software, which identified two B/F breakpoints: the first one located at nucleotide 748 (numbered on the basis of the HXB-2 strain [GenBank Accession Number M38432]) approximately 50 nucleotides upstream of the starting codon of the p17 protein; the second in the p24 coding region at nucleotide 1288. When previously characterized B/F recombinant HIV-1 sequences were included in the phylogenetic analysis, the sequence clustered closely with B/F recombinant sequences of various South American origins (88% bootstrap support). A relationship with South American CRF12_BF was suggested by the presence of the amino acid signature Val at Position 9 in p2gag.


156x134mm (150 x 150 DPI)

Figure 2. CD4+ lymphocyte T cell count.



The Figure shows the immunological recovery under treatment. Baseline mean values are similar ($p=0.79$); after the beginning of HAART, the mean CD4+ cell count increases in both groups but with a better response in the PI-based treatment arm. This difference is statistically significant from week 36 onwards ($p=0.08$). P: t-Student test.

143x113mm (150 x 150 DPI)

Figure 3. Viral decay after treatment initiation.

The Figure shows the viral decay after treatment initiation. Baseline mean HIV-RNA values are similar in PI-based and NNRTI-based treatment arms ($p=0.26$). Both groups showed a virologic response that was similar at each time point. After 4, 12 and 24 weeks of treatment, HIV-RNA was still detectable with similar values ($p=0.31$, 0.97 , 0.30 respectively). The viral undetectability (HIV-RNA <1.69 log₁₀) was reached only at week 36 with either PIs and NNRTIs. P: t-Student test.

184x137mm (150 x 150 DPI)

1
2
3 **A cluster of patients with recombinant B/F HIV-1 infection: epidemiological, clinical and**
4 **virological aspects.**
5
6
7

8
9 Roberto Rossotti^{1*}, Barbara Foglieni², Chiara Molteni¹, Manuela Gatti¹, Irene Guarnori², Ennio La
10
11 Russa¹, Daniele Prati², Anna Orani¹.
12
13

14
15 ¹Department of Infectious Diseases and Tropical Medicine, AO “Alessandro Manzoni”, Lecco,
16
17 Italy; ²Department of Transfusion Medicine and Hematology, AO “Alessandro Manzoni”, Lecco,
18
19 Italy.
20
21

22
23 ***Correspondence to: Roberto Rossotti**
24
25

26
27 **E-mail: r.rossotti@ospedale.lecco.it**
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 **Abstract.** Migratory processes have caused changes in HIV epidemiology and non-B subtypes are
8
9 now playing an increasing role. In a cohort of 553 HIV-infected outpatients tested to identify non-B
10
11 isolates, the largest group consisted of 13 subjects with a recombinant B/F form (prevalence 2.4%).
12
13 Sequencing and phylogenetic analyses described a B/F recombinant clade with anomalous
14
15 breakpoints that did not allow it to be classified as CRF12_BF. Viral load was not quantified
16
17 efficiently because of a mismatch in the primers and probes used by commercial assays. An
18
19 assessment of the clinical management, and epidemiological, immunological and virological
20
21 characteristics of these patients, who were receiving non-nucleoside reverse transcriptase inhibitor
22
23 (NNRTI)- or protease inhibitor (PI)-based regimens, showed that the immunological and virological
24
25 mismatch delayed the start of treatment by a mean of 6.8 months. Therapy was started in nine
26
27 patients. Both NNRTI- and PI-based regimens led to full virological suppression after a mean 36
28
29 weeks of treatment; the PI-based regimens proved to be more effective in terms of immunological
30
31 recovery (1341 *versus* 544 CD4+ cells/mm³). The spread of non-B subtypes is increasing
32
33 throughout the world but their response to treatment is still unclear. PIs and NNRTIs are effective
34
35 but further tests are needed to allow the more efficient recognition of these viral strains and
36
37 establish how they should be treated.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 **Key words: HIV-1; non-B subtype; B/F recombinant form; response to HAART.**
56
57
58
59
60

1
2
3 **Introduction.** The complex genetic evolution of human immunodeficiency virus (HIV) led to the
4 development of different strains in different geographical regions throughout the world. HIV-1
5 includes three subgroups: M, N and O. The M group is divided into 11 subtypes and includes
6 multiple circulating recombinant forms (CRFs) and unique recombinant forms (URFs).
7
8
9

10
11
12
13
14 Given their different biology, epidemiology and drug-susceptibility, every viral clade may give rise
15 to particular difficulties in clinical management. HIV-1 subtype B is still the most common in
16 Western countries, but immigration is changing the epidemiology of HIV and an increasing role is
17 being played by non-B subtypes. The prevalence of non-B subtypes in Italy increased from 2.6% in
18 the years 1980-1992 to 18.9% in 1993-2008 [Lai et al., 2010]. All of the subtypes (except clade K)
19 and seven CRFs are currently circulating, and subtype F1 is the most prevalent. The prevalence of
20 CRF12_BF is <2% in Northern Italy [Baldanti et al., 2008], whereas the B/F1 recombination is the
21 most common of the URFs. This study was conducted in a general hospital in Lombardy, a
22 Northern Italian region that has many immigrants mainly from West Africa. The prevalence of non-
23 B subtypes among the new HIV diagnoses made over the last 12 months has been 10.3%
24 (unpublished data). To date, there are few data concerning subtype F susceptibility to highly active
25 antiretroviral treatment (HAART) and information about CRF12_BF and B/F URFs is even scarcer.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 The case of a blood donor with HIV antibodies in whom it was difficult to detect HIV RNA using
44 routine assays showed that problems can arise in identifying potentially infectious blood units
45 [Foglieni et al., 2010], and a group of patients with discordant immunological and virological
46 patterns (i.e. decreasing CD4+ T lymphocyte cell counts with HIV RNA viral load persistently
47 below 2.6 log₁₀) has also been described. The inefficient quantitation of the circulating virus was
48 due to variations in the conserved *gag* region that reduced or abolished hybridisation with
49 commercial assays. The *gag* sequence showed the presence of a number of sequence variations not
50 belonging to a classic subtype B that hindered real-time PCR amplification.
51
52
53
54
55
56
57
58
59
60

1
2
3 When the HIV-infected outpatient cohort was tested for non-B subtypes, the non-B isolates
4 included a B/F recombinant clade that was similar to CRF12_BF but had anomalous breakpoints.
5
6 Epidemiological aspects and the clinical outcomes of the patients infected by this recombinant form
7
8 were assessed during a follow-up period of 48 weeks.
9
10
11

12
13 **Methods.** The HIV-infected outpatient cohort was tested in parallel using routine and in-house
14 quantitative real-time PCR (qRT-PCR) assays. The routine Roche qRT-PCR assays (COBAS
15 AmpliCor HIV1 Monitor v1.5 and COBAS AmpliPrep/COBAS TaqMan® (CAP/CTM) HIV-1
16 System v.1, Roche Diagnostics, Branchburg, NJ) target a specific sequence located in a highly
17 conserved region of the HIV-1 *gag* gene that can be amplified using the primer pair
18 SSK145_F/SKCC1B_R. The two in-house qRT-PCR-based assays were designed to avoid the
19 regions targeted by the commercial assays and detect the *gag* and the 5'-*ltr* regions. The *env* and
20 *gag* gene regions (including the sequence targeted by the Roche assays) were analysed
21 phylogenetically.
22
23
24
25
26
27
28
29
30
31
32
33
34

35
36 Descriptive statistics were used to analyse the demographic, clinical, immunological and virological
37 characteristics of the patients in order to evaluate possible epidemiological links, and assess the
38 patients' clinical management.
39
40
41
42

43
44 After April 2009, detection was improved by the introduction of the new Roche qRT-PCR assay
45 (CAP/CTM HIV-1 System v.2, Roche Diagnostics, Branchburg, NJ) based on the amplification of
46 two different HIV regions. This assay quantified the actual viral load, and so HAART could be
47 prescribed in accordance with the guidelines. The statistical analysis of the delay in starting
48 HAART was made using only the data collected before the introduction of the new Roche assay.
49
50
51
52
53
54
55

56
57 As the analysis was partially retrospective and the patients were managed in accordance with the
58 current guidelines, no ethical approval was required.
59
60

1
2
3 **Results.** In nineteen of the 553 patients in the HIV-infected outpatient cohort analysed by means of
4 qRT-PCR (3.4%), the viral loads measured by the in-house assays were higher than those measured
5
6 by the routine assays (data not shown). As the in-house assays targeted two different HIV-1 regions,
7
8 it was possible to show that the failure of the commercial assays to quantify the actual viral load
9
10 was due to the presence of base variations in the *gag* region that affected amplification.
11
12

13
14
15
16 Extensive sequencing analyses revealed a number of non-B subtypes, and phylogenetic analysis of
17
18 the whole *gag* and C2V3 regions revealed the presence of a B/F recombinant strain in 13 subjects.
19
20 The *env* sequence clustered with HIV-1 subtype B, and the *gag-protease* sequence belonged to
21
22 subtype F with a section of subtype B, thus suggesting an intersubtype recombination (Fig. 1).
23
24 Phylogenetic analysis of previously characterised B/F recombinant HIV-1 sequences showed that
25
26 all of the sequences of the 13 subjects grouped in the same cluster as B/F recombinant sequences of
27
28 various South American origins, and showed a close relationship with South American CRF12_BF
29
30 [Foglieni et al., 2010]. Two recently described BF URFs from Luxemburg and Brazil (accession
31
32 numbers EU170145 and AY455780 [Thomson et al., 2004]) were the closest to this strain. All of
33
34 the sequences have been deposited in GenBank under accession numbers HQ834729-HQ834742.
35
36
37
38
39

40
41 Table 1 shows the characteristics of the patients with the recombinant form. Its prevalence in the
42
43 cohort was 2.4%, and it was more frequent among heterosexuals (85% versus 15%
44
45 homosexuals/bisexuals and no intravenous drug users). No epidemiological links could be
46
47 established except for three identifiable couples (patients 3 and 4, 6 and 7, and 8 and 9). They
48
49 belonged to different age and social groups, and some of them lived in small secluded mountain
50
51 communities. It seems that the recombinant form penetrated the area recently as it was only found
52
53 in subjects diagnosed after 2006 (excluding patient 5, who had an older infection but moved to
54
55 Lecco in 2006). It has not yet been possible to identify any clear introductory event.
56
57
58
59
60

1
2
3 It is worth noting that patient 3 was diagnosed simultaneously with HIV infection and a non-
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

It is worth noting that patient 3 was diagnosed simultaneously with HIV infection and a non-Hodgkin lymphoma, and so HAART was started even though there was no detectable HIV RNA. Analysis of an older stored plasma sample made it possible to include his strain in the same recombinant B/F cluster but, as no other samples could be evaluated retrospectively, his immunological and virological status were not considered in the further analyses.

The mismatch between immunological and virological status led to an average 6.8 months' delay in starting HAART, at which time the patients had a mean CD4+ count of 229 cells/mm³ (range 146-285). The delay was due to the need to repeat confirmatory tests and respect patient wishes (patient 2 refused to start therapy with an undetectable viral load despite his poor immunological status).

Baseline genotypic tests revealed a few mutations in the *rt* and *pol* regions. Nine patients started therapy with non-nucleoside reverse transcriptase inhibitor (NNRTI)-based or protease inhibitor (PI)-based regimens (Tab. 2). The NNRTI backbone was emtricitabine/tenofovir (FTC/TDF) in seven patients and lamivudine/abacavir (3TC/ABC) in two. Patient 9 received the combination FTC/TDF + nevirapine (NVP) and showed virological failure: after six months of treatment, the viral load was 3.82 log₁₀. A new genotypic resistance test revealed the development of two NNRTI-associated mutations (103N and 181C), and so NVP was replaced by atazanavir/ritonavir (ATV/rbv) and the patient slowly achieved full virological suppression.

Figure 2 shows the CD4+ cell counts. There were no significant differences between the two treatment groups at baseline, but the PI-based regimens led to greater improvements and, by week 48, there was a statistically significant between-group difference in mean CD4+ cell counts (1341 vs 544 cells/mm³; p<0.000).

Figure 3 shows viral decay in the two treatment groups. Responses were slow, and viral load became undetectable in both groups after a mean 36 weeks of treatment, with no statistically significant difference at any of the timepoints. There was only one virological failure in the NNRTI

1
2
3 group (patient 9 described above); the presence of mutations in proviral DNA could not be excluded
4
5 given the rapid development of the two substitutions typically associated with NNRTI-based
6
7 regimens. No AIDS-related illnesses or other serious adverse events were recorded.
8
9

10
11 **Discussion.** The spread of non-B subtypes is increasing throughout the world, but their response to
12
13 HAART is still unclear. B/F recombinants have spread from Asia [Leung et al., 2010] to Southern
14
15 American regions outside Brazil [Espinosa et al., 2004]. The prevalence of the recombinant form
16
17 detected in the outpatient cohort described above was slightly higher than that usually found in
18
19 Italy, and probably reflects the high rates of immigration involving Lombardy. Three of the patients
20
21 had extra-European origins, but came from different macro-areas (South America, East Africa and
22
23 West Africa): subtype F is circulating in these areas, but it is unlikely that they brought such closely
24
25 related viral strains from their own countries. It seems that this recombinant cluster has developed
26
27 locally and that the mixing of non-B subtypes with native viruses is ongoing. Furthermore, the
28
29 study findings confirmed that non-B subtypes are more common among heterosexuals, as has been
30
31 found in both Italy [Balotta et al., 2007] and the UK [Booth et al., 2007].
32
33
34
35
36
37

38
39 The clinical management of these infections remains uncertain. There is a recent case report
40
41 concerning a patient with an infection sustained by an underrated B/F recombinant virus who
42
43 experienced a poor outcome [Bolivar et al., 2009]. Because of his low viral load, the patient was not
44
45 treated until he developed an AIDS-defining illness. No AIDS-defining infections were observed in
46
47 the cohort described in this report, although the CD4+ cell counts of two patients fell to below the
48
49 threshold of 200 cells/mm³. These experiences underline the risk that such recombinant viruses may
50
51 affect the reliability of current virological methods, thus limiting correct clinical management and
52
53 allowing a dangerous level of immune impairment.
54
55
56
57

58
59 The susceptibility of subtype F to the currently available drugs has not been studied in detail.
60
Genotype resistance tests do not provide any strong information because their reliability is limited

1
2
3 by technical problems of amplifying and interpreting amino acid sequences, although there is no
4
5 evidence that non-B subtypes develop different drug resistance mutations or have different
6
7 phenotype susceptibility [Visco-Comandini and Balotta, 2003]. According to the International
8
9 AIDS Society algorithm used in this study [Johnson, 2008], the amino acid substitutions may be
10
11 clinically irrelevant, but it should be noted that the most frequent substitution (36I in the *pol* region,
12
13 which has a prevalence of 85.7%) is one of the eight differences in protease protein between the
14
15 subtype F and US subtype B consensus sequences [Waléria-Aleixo et al., 2008].
16
17
18

19
20
21 The choice of the best treatment remains difficult. Apetrei *et al.* [1998] have evaluated the *in vitro*
22
23 effectiveness of a number of drugs against Romanian F strains, and found that their susceptibility to
24
25 zidovudine, lamivudine, NVP, delavirdine, saquinavir and ritonavir was similar to what observed
26
27 for subtype B, whereas they showed natural resistance to a TIBO derivative (R82913), a forerunner
28
29 NNRTI that never entered clinical practice. A more recent *in vitro* study has shown that subtype F is
30
31 less susceptible to amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir than subtype
32
33 B viruses [Krauchenco et al., 2009], but the PI used in the present study (ATV) was not tested.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3 A recent meta-analysis has highlighted the lack of knowledge of subtype F [Martinez-Cajas et al.,
4
5
6 2009].
7

8
9 In our experience, NNRTIs and PIs led to similar virological responses: both treatments achieved
10
11 full virological control, although more slowly than in the case of subtype B viruses. Immunological
12
13 recovery was better with PI-based regimens, as has been previously noted [Riddler et al., 2008;
14
15 Daar et al., 2010].
16
17

18
19 The main limitation of the present study is the sample size and, as only a few patients started
20
21 HAART, there was no randomization. Nevertheless, the two groups were homogeneous in terms of
22
23 baseline immunological and virological status, and duration of infection. To the best of our
24
25 knowledge, this is the first time that such a recombinant viral strain has been analyzed in terms of
26
27 clinical outcomes, CD4+ cell count recovery and virological suppression for an evaluable follow-up
28
29 period.
30
31
32

33
34 It is difficult to compare the clinical management of the clade described in this paper with that of
35
36 the B/F strains found in South America: although recombinant forms are more frequent among
37
38 heterosexuals in both settings, other factors are different, especially the drugs used, and the
39
40 published studies do not exhaustively analyze PIs such as ATV or darunavir, which are commonly
41
42 used in Western countries [Gomes da Silva et al., 2010]. Furthermore, the prevalence of resistance-
43
44 associated mutations in Brazil is higher than that found in this cohort [de Sa-Filho et al., 2009].
45
46 Finally, data generated in countries in which recombinant forms are more common cannot be
47
48 directly transferred to Western countries, where such forms arrived later.
49
50
51
52

53
54 The findings of this study suggest that, if good adherence is ensured, NNRTIs and PIs are both
55
56 effective in treating recombinant B/F virus, and similar findings were made in a recent study of a
57
58 large Italian resistance database including a number of non-B subtypes [Franzetti et al., 2010].
59
60 However, although the responses to HAART do not seem to be significantly different [Geretti,

1
2
3 2006], further analyses are needed to identify the biological differences among HIV-1 subtypes
4
5 because the limited reliability of current diagnostic methods could be dangerous as there is a risk
6
7 that HAART may be delayed, thus leading to more rapid clinical progression. PI- and NNRTI-based
8
9 regimens may be effective but complete virological suppression was obtained slowly, and this needs
10
11 to be taken into account when evaluating treatment responses. As antiretroviral drugs are developed
12
13 for subtype B, it is important to determine whether sequence variability affects progression rates,
14
15 drug susceptibility, treatment responses, and resistance pathways.
16
17
18
19
20
21
22
23

24 **Conflict of interest:** None of the authors has any conflict of interest to declare.
25
26

27 **Acknowledgements.** The authors would like to thank Stefano Rusconi for reading the manuscript
28
29 critically and his valuable grammatical advice.
30
31
32

33 **Financial support:** The laboratory analyses were partially supported by grants from FP6 EC
34
35 (SP23-CT-2006-006487) and COPEV (Comitato per la Prevenzione dell'Epatite Virale, Milan,
36
37 Italy).
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

Abecasis AB, Deforche K, Snoeck J, Bacheler LT, McKenna P, Carvalho AP, Gomes P, Camacho RJ, Vandamme AM. 2005. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-I non-B subtypes C, F and G. *AIDS* 19:1799-1806.

Apetrei C, Descamps D, Collin G, Loussert-Ajaka I, Damond F, Duca M, Simon F, Brun-Vézinet F. 1998. Human Immunodeficiency Virus Type 1 reverse transcriptase sequence and drug susceptibility. *J Virol* 72:3534-3538.

Baldanti F, Paolucci S, Ravasi G, Maccabruni A, Moriggia A, Barbarini G, Maserati R. 2008. Changes in circulation of B and non-B HIV strains: spotlight on a reference centre for Infection Diseases in Northern Italy. *J Med Virol* 80:947-952.

Balotta C, Facchi G, Violin M, Van Dooren S, Cozzi-Lepri A, Forbici F, Bertoli A, Riva C, Senese D, Caramello P, Carnevale G, Rizzardini G, Cremonini L, Monno L, Rezza G, Perno CF, Ippolito G, d'Arminio Monforte A, Vandamme AM, Moroni M, ICONA Study Group. 2007. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. *J Acquir Immune Defic Syndr* 27:499-505.

Bolivar H, Geffin R, Manzi G, Fischl MA, Holzmayer V, Mak WB, Abravaya K, Hackett J Jr. 2009. The challenge of HIV-1 genetic diversity : discordant CD4+ T-cell count and viral load in an untreated patient infected with a subtype F strain. *J Acquir Immune Defic Syndr* 52:659-661.

Booth CL, Garcia-Diaz AM, Youle MS, Johnson MA, Phillips A, Geretti AM. 2007. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. *J Antimicrob Chemother* 59:517-524.

1
2
3 Calazans A, Brindeiro R, Brindeiro P, Verli H, Arruda MB, Gonzalez LM, Guimaraes JA, Diaz RS,
4
5 Antunes OA, Tanuri A. 2005. Low accumulations of L90M in protease from subtype FHIV-I with
6
7 resistance to protease inhibitors is caused by the L89M polymorphism. *J Infect Dis* 191:1961-1970.

8
9
10
11 Cavalcanti AM, Lacerda HR, Brito AM, Pereira S, Medeiros D, Oliveira S. 2007. Antiretroviral
12
13 resistance in individuals presenting therapeutic failure and subtypes of the human
14
15 immunodeficiency virus type I in the Northeast region of Brazil. *Mem Inst Oswaldo Cruz* 102:785-
16
17 792.

18
19
20
21 Daar E, Tierney C, Fischl M, Collier A, Mollan K, Budhathoki C, Godfrey C, Jahed D, Katzenstein
22
23 D, Sax P, ACTG 5202 Study Team. 2010. ACTG 5202: Final Results of ABC/3TC or TDF/FTC
24
25 with either EFV or ATV/r in Treatment-naive HIV-infected Patients. 17th CROI, San Francisco,
26
27 CA, 59LB.

28
29
30
31 De Sa-Filho DJ, Ambar RF, Duarte NB, Matias RB, Candido V, Gagliani LH, Caseiro MM. 2009.
32
33 HIV type 1 diversity from newly diagnosed patients in Santos metropolitan area/Brazil. *AIDS Res*
34
35 *Hum Retroviruses* 25:925-929.

36
37
38
39 Espinosa A, Vignoles M, Gómez Carrillo M, Sheppard H, Donovan R, Peralta LM, Rossi D,
40
41 Radulich G, Salomón H, Weissenbacher M. 2004. Intersubtype BF recombinants of HIV-1 in a
42
43 population of injecting drug users in Argentina. *J Acquir Immune Defic Syndr* 36:630-636.

44
45
46
47
48
49 Foglieni B, Candotti D, Guarnori I, Raffaele L, Berzuini A, Spreafico M, Orani A, Rossotti R,
50
51 Rossi D, Allain JP, Prati D. 2010. A cluster of Human Immunodeficiency Virus type 1 recombinant
52
53 form escaping detection by commercial genomic amplification assays. *Transfusion* doi:
54
55 10.1111/j.1537-2995.2010.02942.x. [Epub ahead of print].

56
57
58
59 Franzetti M, Casazza G, Meini G, Callegaro AP, Corsi P, Maggiolo F, Boeri E, Paolucci N,
60
Gianotti N, Francisci D, Orani A, Filice G, Carli T, Zazzi M, Balotta C. 2010. Evaluation of

1
2
3 virological response to cART in patients carrying non-B subtype matched for baseline genotype
4
5 with B subtype. *Antivir Ther* 15:A136.
6
7

8
9 Geretti AM. 2006. HIV-1 subtypes: epidemiology and significance for HIV management. *Curr*
10
11 *Opin Infect Dis* 19:1-7.
12
13

14
15 Gomes da Silva MM, Queiroz Telles F, Arns da Cunha C, Rhame FS. 2010. HIV subtype,
16
17 epidemiological and mutational correlations in patients from Paraná, Brazil. *Braz J Infect Dis*
18
19 14:495-501.
20
21

22
23 Johnson VA, Brun-Vézinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM,
24
25 Richman DD. 2008. Update of the drug resistance mutations in HIV-1 : December 2008. *Top HIV*
26
27 *Med* 16:138-145.
28
29

30
31 Krauchenco S, Martins NH, Sances M, Polikarpov I. 2009. Effectiveness of commercial inhibitors
32
33 against F HIV-1 protease. *J Enzyme Inhib Med Chem* 24:638-645.
34
35

36
37 Lai A, Riva C, Marconi A, Balestrieri M, Razzolini F, Meini G, Vicenti I, Rosi A, Saladini F,
38
39 Caramma I, Franzetti M, Rossini V, Galli A, Galli M, Violin M, Zazzi M, Balotta C. 2010.
40
41 Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades. *HIV*
42
43 *Med* 11:593-602.
44
45

46
47 Leung RK, Fong FN, Au TC, Lau IF, Chan PK, Zhang C, Ip PK, Lam C, Lee SS, Tsui SK. 2010.
48
49 An unusual cluster of HIV-1 B/F recombinants in an Asian population. *Int J Infect Dis* 14S3:e294-
50
51 e298.
52
53

54
55 Machado ES, Lambert JS, Watson DC, Afonso AO, da Cunha SM, Nogueira SA, Caride E, Oliveria
56
57 RH, Sill AM, DeVico A, Tanuri A. 2004. Genotypic resistance and HIV-I subtype in Brazilian
58
59 children on dual and triple combination therapy. *J Clin Virol* 30:24-31.
60

1
2
3 Marconi VC, Sunpath H, Lu Z, Koranteng-Apeageyi K, Hampton J, Carpenter S, Giddy J, Ross D,
4
5 Holst H, Losina E, Walker BD, Kuritzkes DR, South Africa Resistance Cohort Study Team. 2008.
6
7 Prevalence of HIV-I drug resistance after failure of a first highly active antiretroviral therapy
8
9 regimen in KwaZulu Natal, South Africa. *Clin Infect Dis* 46:1589-1597.

10
11
12
13 Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. 2009. Differences in resistance mutations
14
15 among HIV-I non-subtype B infections: a systematic review of evidence (1996-2008). *J Int AIDS*
16
17 *Soc* 12:1-11.

18
19
20
21 Munerato P, Sucupira MC, Oliveros MPR, Janini LM, de Souza DF, Pereira AA, Inocencio LA,
22
23 Diaz RS. 2010. HIV type 1 antiretroviral resistance mutations in subtypes B, C and F in the city of
24
25 São Paulo, Brazil. *AIDS Res Hum Retroviruses* 26:265-273.

26
27
28
29 Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW,
30
31 George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW, ACTG
32
33 5142 Study Team. 2008. Class-sparing regimens for initial treatment of HIV-1 infection. *N Engl J*
34
35 *Med* 358:2095-2106.

36
37
38
39 Thomson MM, Sierra M, Tanuri A, May S, Casado G, Manjón N, Nájera R. 2004. Analysis of near
40
41 full-length genome sequences of HIV type 1 BF intersubtype recombinant viruses from Brazil
42
43 reveals their independent origins and their lack of relationship to CRF12_BF. *AIDS Res Hum*
44
45 *Retroviruses* 20:1126-1133.

46
47
48
49 Visco-Comandini U, Balotta C. 2003. Genotypic resistance tests for the management of the HIV-
50
51 infected patient with non-B viral isolates. *Scand J Infect Dis Suppl* 106:75-78.

52
53
54
55 Waléria-Aleixo A, Martins AN, Arruda MB, Brindeiro RM, Da-Silva RM, Nobre FF, Greco DB,
56
57 Tanuri A. 2008. Drug resistance mutations profile and accumulation kinetics in Human
58
59 Immunodeficiency Virus-positive individuals infected with Subtypes B and F failing Highly Active
60

1
2
3 Antiretroviral Therapy are influenced by different viral codon usage patterns. Antimicrob Agents
4
5 Chemother 52:4497-4502.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review